PARP-1-IN-3

Research use only, not for human use.

PARP-1-IN-3 is a potent PARP-1 inhibitor that inhibits PARP-1 and PARP-2 with IC50 values of 0.25 nM and 2.34 nM, respectively.

PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer.

Apoptosis Analysis Cell Line:HCT116 cells Concentration:0.3, 1.5, 7.5 μM Incubation Time:48 and 72 h Result:Increased the percentage of total apoptotic cells from 1.05% (control group) to 79.49% (7.5 μM).Cell Cycle Analysis Cell Line:HCT116 cells Concentration:0.3, 1.5, 7.5 μM Incubation Time:48 and 72 h Result:Blocked the cell cycle progression at G2/M phase.Western Blot Analysis Cell Line:HCT116 cells Concentration:0.3, 1, 3 μM Incubation Time:48 h Result:Increased expression levels of γH2AX in a concentration-dependent manner.Western Blot Analysis Cell Line:HCT116 cells Concentration:0.3, 1, 3 μM Incubation Time:48 h Result:Increased the expression levels of Bax, cleaved Caspase-3 and cleaved-PARP, and decreased the expression level of Bcl-2.

——

——

Cell Cycle/DNA Damage

PARP

PARP | Apoptosis

——

——

2976342-33-1

425.28

C21H17BrN2O3

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (293.92 mM; Ultrasonic )

O=C(N)C=1C=CC=CC1OCC=2C=CC=C(C2)NC(=O)C3=CC=C(Br)C=C3

——

(-20℃)

With Ice Pack

≥ 2 years